This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Calvert, A. H. Articles by Plummer, R. PubMed PubMed Citation Articles by Calvert, A. H. Articles by Plummer, R. Related Collections Clinical Research Clinical Research: Clinical Pharmacology

The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical Trials

Authors' Affiliations: Newcastle General Hospital, New Castle, United Kingdom

Requests for reprints: A. Hilary Calvert, Newcastle General Hospital, Framlington Place, Newcastle NE2 4HH, United Kingdom. Phone: 44-191-256-3599; Fax: 44-191-273-4867; E-mail: hilary.calvert{at}newcastle.ac.uk.

Abstract

Although the concept of a phase 0 trial is a relatively new one, there has been a slowly increasing trend toward basing early clinical trial designs on pharmacokinetic and pharmacodynamic end points that has been developing over many years. This article will review the early cancer trial methodologies and the various techniques that have been used to refine them. Several illustrative examples will be presented showing their relevance to trial designs using pharmacodynamic end points and targeted agents. Some criteria for characterizing suitable phase 0 end points are suggested. Four trial designs that are essentially developed for cytotoxic agents using the maximal tolerated dose as an end point are described. Although these trials were not designed with the use of more sophisticated pharmacodynamic end points (such as the measurement of the effect of a targeted agent on its target), they have been developed to optimize the speed with which a dose needed to achieve a particular effect can be determined and are, to this extent, relevant to the design of studies with pharmacodynamic end points.

This article has been cited by other articles:

				G. C. Prendergast Translational Research: Speeding New Concepts between Lab and Clinic Cancer Reviews Online Content, July 1, 2008; 2008(7): 13 - 14. [Full Text] [PDF]

				J. H. Doroshow and R. E. Parchment Oncologic Phase 0 Trials Incorporating Clinical Pharmacodynamics: from Concept to Patient Clin. Cancer Res., June 15, 2008; 14(12): 3658 - 3663. [Abstract] [Full Text] [PDF]

				D. Jacobson-Kram and G. Mills Leveraging Exploratory Investigational New Drug Studies to Accelerate Drug Development Clin. Cancer Res., June 15, 2008; 14(12): 3670 - 3674. [Abstract] [Full Text] [PDF]

				A. J. Murgo, S. Kummar, L. Rubinstein, M. Gutierrez, J. Collins, R. Kinders, R. E. Parchment, J. Ji, S. M. Steinberg, S. X. Yang, et al. Designing Phase 0 Cancer Clinical Trials Clin. Cancer Res., June 15, 2008; 14(12): 3675 - 3682. [Abstract] [Full Text] [PDF]

				H. Eliopoulos, V. Giranda, R. Carr, R. Tiehen, T. Leahy, and G. Gordon Phase 0 Trials: An Industry Perspective Clin. Cancer Res., June 15, 2008; 14(12): 3683 - 3688. [Abstract] [Full Text] [PDF]